“…Previous studies showed that the scale eff ect, competition, and technology spillover are positive externalities of industrial agglomeration (Andersson et al, 2019;Choi, 2020), which explain the promotion effect of pharmaceutical industrial agglomeration on innovation. The results of columns ( 2), ( 4), and (6) revealed that the agglomeration of pharmaceutical development zones, represented by the medicine valley index, exerted no signifi cant infl uence on R&D investment and new product sales, and the coeffi cient of its infl uence on the number of patent applications was 0.250, which was only signifi cant at the 10 percent p-value level.…”